EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC 4.0

Psoriasis Risk Is Lower in Type 2 Diabetes Patients Using Dipeptidyl Peptidase‐4 Inhibitors or Thiazolidinediones Compared to Sulfonylureas

Wei-Sheng Chen iD, Tzu-Min Lin iD, Yu-Sheng Chang iD, Yu-Chuan Shen iD, Hui-Ching Hsu iD, Tzu-Tung Kuo iD, Shu-Chuan Chen, Jin-Hua Chen iD, Chi-Ching Chang iD

Clinical and Translational Science · 2025

DOI: 10.1111/cts.70177 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Clinical and Translational Science, 2025. Verfasst von Wei-Sheng Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Taipei Veterans General Hospital, National Yang-Ming Chiao Tung Un…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Dipeptidyl-Peptidase IV Inhibitors, Psoriasis, Sulfonylurea Compounds. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The risk of psoriasis in diabetic patients has rarely been explored. This study aims to compare the risk of incident psoriasis in patients with Type 2 diabetes (T2D) who initiate dipeptidyl peptidase‐4 inhibitors (DPP‐4is) or thiazolidinediones (TZDs) with those who initiate sulfonylureas, the most common second‐line glucose‐lowering therapy, in addition to metformin monotherapy. This sequential, propensity‐score‐matched, new‐user comparative effectiveness study utilized a target trial emulation framework. It included adults with T2D receiving metformin monotherapy, using data from 2006 to 2015 from a general population database in Taiwan. The primary outcome was the incidence of psoriasis, determined through diagnoses recorded in urgent care, hospital, and outpatient department records. Cox proportional hazards and Poisson regressions with 1:4 propensity score matching was employed to evaluate the risk factors for psoriasis after adjusting for comorbidities and the use of other medications. In 49,810 propensity score‐matched adults with T2D (27,630 men [55.4%]; mean age 57.5 years) identified in the database, the incidence rate of psoriasis in DPP‐4i users was 188 cases per 100,000 person‐years, lower than in sulfonylurea users (467 cases per 100,000 person‐years), with a hazard ratio(HR) of 0.422 (95% CI, 0.273–0.716). For the TZD vs. sulfonylurea comparison, the HR was 0.35, but the smaller matched dataset resulted in wide confidence intervals. The findings suggest that the use of DPP‐4is is associated with a lower risk of psoriasis compared to sulfonylureas in patients with T2D. These results can guide the selection of glucose‐lowering therapies in T2D patients who are at risk of developing psoriasis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsPsoriasisSulfonylurea CompoundsHypoglycemic AgentsThiazolidinedionesHumansMaleFemaleMiddle AgedTaiwanIncidenceAgedRisk FactorsAdultPropensity ScoreMetformin

Stichwörter der Autor:innen

dipeptidyl peptidase‐4 inhibitorspsoriasisthiazolidinedionestype 2 diabetes mellitus

Substanzen

Dipeptidyl-Peptidase IV InhibitorsSulfonylurea CompoundsHypoglycemic AgentsThiazolidinedionesMetformin

Autor:innen und Institutionen

  • Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Taipei Veterans General Hospital, National Yang-Ming Chiao Tung University, Taipei, Taiwan.
  • Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
  • Division of Rheumatology, Immunology and Allergy, Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan.
  • Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, Taipei, Taiwan.
  • Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Wang Fang Hospital, Taipei Medical University, Taipei, Taiwan.
  • Biostatistics Center, College of Management, Taipei Medical University, Taipei, Taiwan.

ORCID-Profile: Wei-Sheng Chen, Tzu-Min Lin, Yu-Sheng Chang, Yu-Chuan Shen, Hui-Ching Hsu, Tzu-Tung Kuo, Jin-Hua Chen, Chi-Ching Chang

Zitieren

APA

Chen, W. S., Lin, T. M., Chang, Y. S., Shen, Y. C., Hsu, H. C., Kuo, T. T., Chen, S. C., Chen, J. H., & Chang, C. C. (2025). Psoriasis Risk Is Lower in Type 2 Diabetes Patients Using Dipeptidyl Peptidase‐4 Inhibitors or Thiazolidinediones Compared to Sulfonylureas. Clinical and Translational Science. https://doi.org/10.1111/cts.70177

Vancouver

Chen WS, Lin TM, Chang YS, Shen YC, Hsu HC, Kuo TT, et al. Psoriasis Risk Is Lower in Type 2 Diabetes Patients Using Dipeptidyl Peptidase‐4 Inhibitors or Thiazolidinediones Compared to Sulfonylureas. Clinical and Translational Science. 2025. doi:10.1111/cts.70177

BibTeX
@article{Chen2025,
  author = {Chen, Wei-Sheng and Lin, Tzu-Min and Chang, Yu-Sheng and Shen, Yu-Chuan and Hsu, Hui-Ching and Kuo, Tzu-Tung and Chen, Shu-Chuan and Chen, Jin-Hua and Chang, Chi-Ching},
  title = {Psoriasis Risk Is Lower in Type 2 Diabetes Patients Using Dipeptidyl Peptidase‐4 Inhibitors or Thiazolidinediones Compared to Sulfonylureas},
  journal = {Clinical and Translational Science},
  year = {2025},
  doi = {10.1111/cts.70177}
}
Kostenlos starten →